Welcome to our dedicated page for GeoVax Labs Warrants news (Ticker: GOVXW), a resource for investors and traders seeking the latest updates and insights on GeoVax Labs Warrants stock.
GeoVax Labs, Inc. (OTCQB: GOVX) is a clinical-stage biotechnology company specializing in developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers.
Utilizing novel proprietary platforms like the modified vaccinia ankara - virus-like particle (MVA-VLP) vaccine platform, GeoVax's pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and gene-directed therapy for head and neck cancers.
Additional research programs focus on preventive vaccines against infectious diseases like Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, along with immunotherapies for various solid tumors.
Recent achievements include positive initial safety and immune response findings from a Phase 2 clinical trial evaluating GEO-CM04S1, the COVID-19 vaccine, as a heterologous booster in 63 healthy adults who previously received the Pfizer or Moderna mRNA vaccine. The trial has demonstrated statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants.
GeoVax Labs, Inc. (GOVX) announced financial results for 2022, reporting a net loss of $14 million, down from $18.6 million in 2021. The company successfully raised approximately $35.4 million through equity offerings, boosting cash to $27.6 million. Key operational advancements include the Phase 1/2 expansion of Gedeptin® for advanced head and neck cancer and ongoing Phase 2 trials for the GEO-CM04S1 COVID-19 vaccine, showing robust immune responses. GeoVax also secured rights for NIH-MVA technology, aiming to be a primary supplier of MVA vaccines against Monkeypox and Smallpox. A conference call is scheduled for further discussions.
GeoVax Labs, Inc. (Nasdaq: GOVX) will report its 2022 financial results on March 23, 2023, after market close. The announcement will be followed by a live conference call at 4:30 PM ET, providing a general business update and financial discussion. Investors and analysts can join the call via domestic and international numbers or through a provided webcast link. GeoVax is developing innovative vaccines and immunotherapies for cancer and infectious diseases, including a next-generation COVID-19 vaccine, GEO-CM04S1, currently in two Phase 2 trials targeting high-risk populations.
GeoVax Labs (Nasdaq: GOVX) has announced that its Chairman and CEO, David Dodd, will discuss the company's advancements during a fireside chat at the 35th Annual Roth Conference on March 14, 2023, at 12:30 PM PT. The discussion, led by Senior Research Analyst Kumaragura Raja, Ph.D. from ROTH MKM, will focus on GeoVax's progress in developing immunotherapies and vaccines against cancers and infectious diseases. The company is conducting Phase 1/2 trials for its Gedeptin® therapy and Phase 2 trials for its next-generation COVID-19 vaccine, GEO-CM04S1. Investors can view the webcast of the event here.
GeoVax Labs has presented promising clinical trial results for its HIV vaccine candidate, MVA62B, at the Conference on Retroviruses and Opportunistic Infections held in Seattle. The trial, led by UCSF researchers, focuses on a combinational therapy aimed at achieving a functional cure for HIV, demonstrating high immunogenicity and enhanced T cell responses. The findings suggest potential efficacy in reducing viral replication without traditional antiviral medications. The company continues its commitment to developing immunotherapies for various viral diseases, including COVID-19 and others.
GeoVax Labs, Inc. (GOVX) has announced a collaboration with EmVenio Research to deploy a mobile clinical facility in Claremont, California, to enhance patient recruitment for its ongoing Phase 2 trial of the GEO-CM04S1 COVID-19 booster vaccine. This initiative aims to facilitate access to clinical trials for diverse populations, with a focus on evaluating the vaccine's safety and immunogenicity in healthy patients. GEO-CM04S1 is targeting individuals who have previously received FDA-approved mRNA vaccines. The trial will measure immune responses, including neutralizing antibodies and T-cell responses, to assess its effectiveness against COVID-19.
GeoVax Labs, a biotechnology firm, announced progress in developing a continuous avian cell line system for its MVA-based vaccines and immunotherapies. This new manufacturing method aims to improve efficiency and reduce costs, transitioning from the traditional chicken embryonic fibroblast process. CEO David Dodd emphasized that this transformation will enable timely global responses to health threats and broaden MVA applications. Currently, GeoVax is engaged in clinical trials for its COVID-19 vaccine targeting high-risk populations. The company aims to lead in MVA-based vaccine production, including for diseases like Mpox and Smallpox.
GeoVax Labs (Nasdaq: GOVX) has announced that its Phase 1/2 clinical trial for Gedeptin®, aimed at treating recurrent head and neck cancers, is now actively enrolling patients at Stanford, Emory, and Thomas Jefferson Universities. The trial evaluates the safety and efficacy of Gedeptin with up to five treatment cycles involving intra-tumoral injections. Preliminary results from a prior study indicated that Gedeptin was well-tolerated and showed tumor size reduction. The FDA has granted Gedeptin orphan drug status, which may facilitate further investigations and collaboration in cancer treatment.
GeoVax Labs, Inc. (Nasdaq: GOVX) announced that its Chairman and CEO, David Dodd, will present at the 2023 BIO CEO & Investor Conference in New York City and virtually from February 6-9, 2023. Dodd's live presentation is scheduled for February 7 at 3:45 PM EST, with an on-demand video also available. The company will hold one-on-one meetings to discuss their innovative therapies and vaccines for cancers and infectious diseases, including the novel COVID-19 vaccine GEO-CM04S1, currently in Phase 2 trials. Interested parties can schedule meetings through the conference page or contact Investor Relations.
GeoVax Labs, Inc. (GOVX) announced a significant achievement in its Zika vaccine development, receiving a Notice of Allowance for its patent application related to its novel vaccine candidate, GEO-ZM02. Preclinical studies showed that a single dose of this vaccine provided 100% protection against a lethal dose of the Zika virus. This promising outcome highlights the vaccine's potential to protect vulnerable populations, particularly women of childbearing age and newborns, against Zika-related diseases. Additionally, GeoVax is advancing its MVA-based next-generation COVID-19 vaccine, currently in Phase 2 trials, further solidifying its commitment to addressing critical infectious diseases.
FAQ
What is the current stock price of GeoVax Labs Warrants (GOVXW)?
What is GeoVax Labs, Inc. focused on developing?
What recent achievements has GeoVax Labs, Inc. made?
Which diseases are targeted by GeoVax's vaccine development programs?
